Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pivotal Therapeutics Inc. recently announced encouraging top line data from the REVEAL study (n=110) on its cardiovascular candidate Vascazen in the US. Vascazen was successful in achieving the primary objective of the study of correcting Omega-3 deficiency.

Results from the study also revealed that Vascazen gained statistical significance in several other secondary objectives in patients having elevated triglycerides. The REVEAL trial is a randomized, double blind, placebo controlled, multi-center study. Pivotal Therapeutics enrolled 110 patients for the study.

The study evaluated the effects of Vascazen in the correction of Omega-3 deficiency in patients suffering from cardiovascular disease and having one or more risk factors associated with it. Moreover, the concomitant effects of Vascazen on cardiovascular risk factors including triglycerides, very-low-density lipoprotein (VLDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol among others, were also evaluated.

Pivotal Therapeutics stated in its press release that the positive top line data from the REVEAL study on Vascazen has been accepted for presentation at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013 Scientific Sessions (ATVB).

We note that the cardiovascular market currently includes big players like Roche Holding (RHHBY - Analyst Report) and Sanofi (SNY - Analyst Report).

We note that Vascazen is the lead product at Pivotal Therapeutics. Vascazen is formulated to meet the dietary Omega-3 deficient needs of patients suffering from cardiovascular diseases.

Pivotal Therapeutics currently carries a Zacks Rank #3 (Hold). Meanwhile other speciality pharmaceutical companies such as Biodel Inc. (BIOD - Snapshot Report) currently look better positioned. Biodel carries a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%